首页> Heliyon> CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).

CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).

导出 LinkOut

翻译打印收藏纠错

第一作者： Ji-Hea,Kim

第一单位： Institute of Stem Cell Research, Korea University College of Medicine, Seoul, South Korea.;Department of Biomedical Science, Graduate School of Medicine, Korea University, Seoul, South Korea.

作者： Ji-Hea,Kim ^[1] ; Ka-Won,Kang ^[2] ; Yong,Park ^[2] ; Byung Soo,Kim ^[2]

作者单位： Institute of Stem Cell Research, Korea University College of Medicine, Seoul, South Korea.;Department of Biomedical Science, Graduate School of Medicine, Korea University, Seoul, South Korea. ^[1] Department of Internal Medicine, Anam Hospital Korea University Medical Center, Seoul, South Korea. ^[2]

关键词 CXCR2 DPP4/CD26 GRO-A IL-8 Leukemic stem cells Ponatinib-resistant CML Tyrosine kinase inhibitors

DOI 10.1016/j.heliyon.2023.e22091

PMID 38045173

发布时间 2023-12-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Heliyon

2023年9卷11期

e22091页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

点击下载本期目录封面

Heliyon

2023年9卷11期

e22091页

检索历史清除

CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).

Heliyon

相似文献

同项目论文

Heliyon

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).

Heliyon

相似文献

同项目论文

Heliyon

相关期刊

检索历史清除